ALLUVI: A DETAILED EXPLORATION INTO RETATRUTIDE'S PROMISE

Alluvi, previously known as LY3414901, represents a significant advancement in obesity management. This dual -action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) target agonist shows remarkable impact in early clinical data, with substantial slimming obse